

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Elixinol Wellness Limited
ABN	34 621 479 794

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Pauline Gately
Date of last notice	18 October 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	1) 31 May 2024 2) 31 May 2024
No. of securities held prior to change	9,930,583 Fully paid Ordinary Shares
Class	Fully paid Ordinary Shares Director Fee Rights
Number acquired	1) 8,442,776 Director Fee Rights 2) 2,814,258 Fully paid Ordinary Shares on vesting of Director Fee Rights

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number disposed	1) Nil 2) 2,814,258 Director Fee Rights converted to Fully Paid Ordinary Shares
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	1) Director Fee Rights issued in lieu of cash consideration with a deemed issue price of \$0.00533 per Director Fee Right. 2) Nil cash consideration paid on vesting of Director Fee Rights
No. of securities held after change	12,744,841 Fully paid Ordinary Shares 5,628,518 Director Fee Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	1) Issue of Director Fee Rights as approved by Shareholders at the Company's Annual General Meeting held on 30 May 2024. 2) Issue of Fully paid Ordinary Shares upon vesting of a portion of Director Fee Rights, as approved by Shareholders at the Company's Annual General Meeting held on 30 May 2024.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.